Respiratory Medicine
Volume 104, Issue 6 , Pages 773-779 , June 2010

Predictors of mortality in COPD

,Revised 17 December 2009 ,Accepted 27 December 2009.

References 

  1. Global burden of disease 2004 update: part 2, causes of death. World Health Organization; 2008;Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_part2.pdf
  2. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet. 1997 May 17;349(9063):1436–1442
  3. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Updated 2007; January 2008. Available from: http://www.goldcopd.org/GuidelinesResources.asp?l1=2&l2=0.
  4. Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946
  5. National Heart Lung and Blood Institute . Morbidity and mortality: 2007 chartbook on cardiovascular, lung, and blood diseases. Bethesda, MD: US Department of Health and Human Services; June 2007;Available from: www.nhlbi.nih.gov/resources/docs/cht-book.htm[cited 2008 March 31]
  6. Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet. 2004 Sep 11–17;364(9438):985–996
  7. Barnes PJ. COPD: is there light at the end of the tunnel?. Curr Opin Pharmacol. 2004 Jun;4(3):263–272
  8. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004 Aug 21–27;364(9435):709–721
  9. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977 Jun 25;1(6077):1645–1648
  10. Bang KM, Gergen PJ, Kramer R, Cohen B. The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest. 1993 Feb;103(2):536–540
  11. Beaty TH, Cohen BH, Newill CA, Menkes HA, Diamond EL, Chen CJ. Impaired pulmonary function as a risk factor for mortality. Am J Epidemiol. 1982 Jul;116(1):102–113
  12. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. Bmj. 1996 Sep 21;313(7059):711–715discussion 5–6
  13. Schunemann HJ, Dorn J, Grant BJ, Winkelstein W, Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo health study. Chest. 2000 Sep;118(3):656–664
  14. Barnes PJ, Celli B. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33:1165–1185
  15. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004 Jul;59(7):574–580
  16. Cote C, Pinto-Plata V, Nekach H, Nguyen M, Dordelly L, Celli B. Co-morbidities in COPD: How many and how significant [abstract]. American Thoracic Society International Conference, Toronto, Canada; May 16–21, 2008. p. Poster Board #730.
  17. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005 Feb 15;142(4):233–239
  18. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax. 2005 Dec;60(12):992–997
  19. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007 Feb 22;356(8):775–789
  20. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med. 2002 Mar 14;346(11):793–801
  21. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med. 2003 Feb 15;167(4):544–549
  22. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J. 2004 Jan;23(1):28–33
  23. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004 Mar 4;350(10):1005–1012
  24. Imfeld S, Bloch KE, Weder W, Russi EW. The BODE index after lung volume reduction surgery correlates with survival. Chest. 2006 Apr;129(4):873–878
  25. Martinez FJ, Han MK, Andrei AC, et al. Longitudinal change in the BODE index predicts mortality in severe emphysema. Am J Respir Crit Care Med. 2008 Sep 1;178(5):491–499
  26. Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005 Mar 15;171(6):591–597
  27. Albuquerque AL, Nery LE, Villaca DS, et al. Inspiratory fraction and exercise impairment in COPD patients GOLD stages II-III. Eur Respir J. 2006 Nov;28(5):939–944
  28. Vassaux C, Torre-Bouscoulet L, Zeineldine S, et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. Eur Respir J. 2008 Nov;32(5):1275–1282
  29. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000 May;117(5 Suppl. 2):398S–401S
  30. Wedzicha JA. Mechanisms of exacerbations. Novartis Found Symp. 2001;234:84–93discussion 103
  31. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (study to understand prognoses and preferences for outcomes and risks of treatments). Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):959–967
  32. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005 Nov;60(11):925–931
  33. Soler-Cataluna JJ, Martinez-Garcia MA, Sanchez LS, Tordera MP, Sanchez PR. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med. 2009 May;103(5):692–699
  34. Barnes PJ, Chowdhury B, Kharitonov SA, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006 Jul 1;174(1):6–14
  35. Barnes NC, Qiu YS, Pavord ID, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med. 2006 Apr 1;173(7):736–743
  36. Spira A, Beane J, Pinto-Plata V, et al. Gene expression profiling of human lung tissue from smokers with severe emphysema. Am J Respir Cell Mol Biol. 2004 Dec;31(6):601–610
  37. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007 Jan 4;356(1):11–20
  38. Sin DD, Man SFP. Pharmacotherapy for mortality reduction in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(7):624–629
  39. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007 Feb 1;175(3):250–255
  40. CRP as predictor of mortality in COPD. In:  DeTorres Celli B editors. Comorbidities in COPD. FL: Jacksonville; 2008 March 10;
  41. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006 Oct 15;174(8):867–874
  42. Pinto-Plata V, Toso J, Lee K, et al. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax. 2007 Jul;62(7):595–601

PII: S0954-6111(10)00008-9

doi: 10.1016/j.rmed.2009.12.017

Respiratory Medicine
Volume 104, Issue 6 , Pages 773-779 , June 2010

Article Tools

* Image Usage & Resolution